Inventiva (IVA) Competitors $5.77 +0.51 (+9.70%) Closing price 04:00 PM EasternExtended Trading$5.76 0.00 (-0.09%) As of 06:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock IVA vs. CNTA, DNLI, IBRX, AGIO, IDYA, OCUL, HRMY, IRON, CGON, and RXRXShould you be buying Inventiva stock or one of its competitors? The main competitors of Inventiva include Centessa Pharmaceuticals (CNTA), Denali Therapeutics (DNLI), ImmunityBio (IBRX), Agios Pharmaceuticals (AGIO), IDEAYA Biosciences (IDYA), Ocular Therapeutix (OCUL), Harmony Biosciences (HRMY), Disc Medicine (IRON), CG Oncology (CGON), and Recursion Pharmaceuticals (RXRX). These companies are all part of the "pharmaceutical products" industry. Inventiva vs. Its Competitors Centessa Pharmaceuticals Denali Therapeutics ImmunityBio Agios Pharmaceuticals IDEAYA Biosciences Ocular Therapeutix Harmony Biosciences Disc Medicine CG Oncology Recursion Pharmaceuticals Inventiva (NASDAQ:IVA) and Centessa Pharmaceuticals (NASDAQ:CNTA) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, dividends, earnings, risk, valuation and profitability. Does the media favor IVA or CNTA? In the previous week, Inventiva and Inventiva both had 14 articles in the media. Centessa Pharmaceuticals' average media sentiment score of 1.30 beat Inventiva's score of 0.37 indicating that Centessa Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inventiva 2 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Centessa Pharmaceuticals 8 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility and risk, IVA or CNTA? Inventiva has a beta of 0.69, suggesting that its stock price is 31% less volatile than the S&P 500. Comparatively, Centessa Pharmaceuticals has a beta of 1.47, suggesting that its stock price is 47% more volatile than the S&P 500. Which has higher earnings and valuation, IVA or CNTA? Inventiva has higher revenue and earnings than Centessa Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInventiva$9.95M55.47-$199.34MN/AN/ACentessa Pharmaceuticals$6.85M311.02-$235.76M-$1.79-8.89 Is IVA or CNTA more profitable? Inventiva's return on equity of 0.00% beat Centessa Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets InventivaN/A N/A N/A Centessa Pharmaceuticals N/A -40.39%-29.87% Do analysts prefer IVA or CNTA? Inventiva presently has a consensus price target of $14.83, suggesting a potential upside of 157.08%. Centessa Pharmaceuticals has a consensus price target of $31.45, suggesting a potential upside of 97.70%. Given Inventiva's higher probable upside, research analysts plainly believe Inventiva is more favorable than Centessa Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Inventiva 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83Centessa Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 12 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders & institutionals have more ownership in IVA or CNTA? 19.1% of Inventiva shares are owned by institutional investors. Comparatively, 82.0% of Centessa Pharmaceuticals shares are owned by institutional investors. 32.0% of Inventiva shares are owned by insiders. Comparatively, 7.1% of Centessa Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. SummaryInventiva and Centessa Pharmaceuticals tied by winning 6 of the 12 factors compared between the two stocks. Get Inventiva News Delivered to You Automatically Sign up to receive the latest news and ratings for IVA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IVA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IVA vs. The Competition Export to ExcelMetricInventivaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$551.96M$3.10B$5.75B$9.83BDividend YieldN/A2.28%6.66%4.49%P/E RatioN/A21.2382.4426.63Price / Sales55.47398.88530.80110.54Price / CashN/A43.5325.7028.92Price / Book-4.778.1310.646.56Net Income-$199.34M-$53.35M$3.28B$266.04M7 Day Performance10.33%0.45%-0.08%-0.58%1 Month Performance79.19%9.94%10.36%6.24%1 Year Performance148.17%11.73%49.00%22.21% Inventiva Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IVAInventiva2.6865 of 5 stars$5.77+9.7%$14.83+157.1%+131.7%$551.96M$9.95M0.00100News CoverageAnalyst ForecastShort Interest ↑Gap UpHigh Trading VolumeCNTACentessa Pharmaceuticals2.7317 of 5 stars$16.79+1.4%$31.50+87.6%+27.9%$2.25B$6.85M-9.38200News CoveragePositive NewsAnalyst ForecastGap UpDNLIDenali Therapeutics4.3108 of 5 stars$15.27-2.4%$33.62+120.1%-36.8%$2.23B$330.53M-5.45430Positive NewsIBRXImmunityBio2.6179 of 5 stars$2.34+0.4%$10.75+359.4%-39.7%$2.21B$14.74M-4.87590AGIOAgios Pharmaceuticals4.3526 of 5 stars$37.71-1.2%$56.33+49.4%-14.5%$2.19B$36.50M3.43390News CoveragePositive NewsIDYAIDEAYA Biosciences4.4111 of 5 stars$24.55-1.5%$47.10+91.9%-35.5%$2.15B$7M-6.4880News CoveragePositive NewsAnalyst ForecastOCULOcular Therapeutix3.6574 of 5 stars$12.21-2.5%$17.20+40.9%+44.0%$2.12B$63.72M-9.54230HRMYHarmony Biosciences4.2812 of 5 stars$36.89-2.8%$51.00+38.2%+3.1%$2.12B$714.73M11.90200Positive NewsIRONDisc Medicine3.2643 of 5 stars$59.650.0%$98.30+64.8%+20.8%$2.07BN/A-13.3430News CoveragePositive NewsCGONCG Oncology3.0333 of 5 stars$26.82+0.4%$54.30+102.5%-25.5%$2.04B$1.14M-15.1561News CoveragePositive NewsAnalyst UpgradeRXRXRecursion Pharmaceuticals2.1023 of 5 stars$4.70-3.3%$7.00+48.9%-36.0%$2.04B$58.84M-2.64400Positive News Related Companies and Tools Related Companies CNTA Competitors DNLI Competitors IBRX Competitors AGIO Competitors IDYA Competitors OCUL Competitors HRMY Competitors IRON Competitors CGON Competitors RXRX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IVA) was last updated on 9/3/2025 by MarketBeat.com Staff From Our PartnersHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Coin Could Explode, and it’s Hiding in Plain Sight!The #1 coin with skyrocket potential right now... Sometimes the biggest opportunities are hiding in plain s...Crypto 101 Media | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inventiva S.A. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Inventiva With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IVA Stock Alerts